60 Degrees Pharmaceuticals, Inc. (SXTP)

SXTP Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-7.82	-7.96	-3.81	-6.18
Depreciation & Amortization	0.07	0.06	0.1	0.08
Stock-Based Compensation	1	3.61	1.9	-
Other Adjustments	0.21	-1.56	-3.13	1.72
Change in Receivables	0	-0.26	-0.19	0.1
Changes in Inventories	-0.37	0.02	0.21	0.01
Changes in Accounts Payable	0.39	0.5	-0.21	0.17
Changes in Accrued Expenses	-0	-0.02	1.27	2.69
Changes in Other Operating Activities	0.07	-0.05	-0.67	0.4
Operating Cash Flow	-6.37	-5.65	-4.54	-1.01
Capital Expenditures	-	-0.1	-0.06	-
Purchases of Intangible Assets	-0.03	-0.08	-0.06	-0.06
Purchases of Investments	-	-1.71	-	-
Investing Cash Flow	-0.1	-1.89	-0.12	-0.06
Long-Term Debt Issued	-	-	0.9	1.29
Long-Term Debt Repaid	-	-	-1.86	-
Net Long-Term Debt Issued (Repaid)	-	-	-0.96	1.29
Issuance of Common Stock	-	7.05	7.44	-
Net Common Stock Issued (Repurchased)	-	7.05	7.44	-
Other Financing Activities	-	-	-	-0.07
Financing Cash Flow	-	7.05	6.47	1.22
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.01	0	0.06	-0
Net Cash Flow	0.39	-0.48	1.88	0.15
Beginning Cash & Cash Equivalents	1.58	2.14	0.26	0.12
Ending Cash & Cash Equivalents	1.97	1.66	2.14	0.26
Free Cash Flow	-6.37	-5.75	-4.6	-1.01
FCF Margin	-646.72%	-844.19%	-1814.28%	-197.57%
Free Cash Flow Per Share	-6.06	-12.65	-69.37	-25.59
Levered Free Cash Flow	-7.67	-8.02	-4.25	-1.55
Unlevered Free Cash Flow	-7.55	-9.31	-4.52	1.6

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q